AMENDMENTS TO THE SPECIFICATION

In the Sequence Listing:

Please insert a paper copy of the sequence listing as new pages 1-2 in the above-mentioned application. A computer readable form copy (CRF copy) of the sequence listing accompanies this response.

Please replace the table on page 27 beginning at line 1, with the following amended table:

Compounds known to be proteasome or NF-κB inhibitors include:

Proteasome Inhibitors	
PSI	N-carbobenzoyl-lle-Glu-(OtBu)-Ala-Leu-CHO
MG-132	N-carbobenzoyl-Leu-Leu-CHO
MG-115	N-carbobenzoyl-Leu-Leu-Nva-CHO
MG-101 or Calpain Inh I	N-Acetyl-Leu-Leu-norLeu-CHO
ALLM	N-Acetyl-Leu-Leu-Met-CHO
	N-carbobenzoyl-Gly-Pro-Phe-Leu-CHO (SEQ ID NO:1)
	N-carbobenzoyl-Gly-Pro-Ala-Phe-CHO (SEQ ID NO:2)
	N-carbobenzoyl-Leu-Leu-Phe-CHO
	N-carbobenzoyl-Leu-Ala-Leu-CHO
Gliotoxin .	OH OCH ₂ OH
SN50	NLS of NF-kB MW 2781
Bay 11-7082	H ₃ C CH ₃
Capsaicin	OH ₂ C CH ₃
PDTC	N—C—SNH ₄
ALLN	N-Acetyl-Leu-Leu-Nle-CHO

Please replace the paragraph beginning on page 39, line 4, with the following amended paragraph:

An assay to test the effect of compounds on the 20S thermophila proteasome activity was employed. Purified 20S thermophila proteasomes and the fluorogenic peptide substrate Suc-Leu-Leu-Val-Tyr-AMC (SEQ ID NO:3) are available from CalBiochem, San Diego, CA. Briefly, serial dilutions of the inhibitor to be tested were mixed with proteasome solution at a concentration of proteasome of 0.01 mg/ml. After 30 min incubation at 37°C, substrate solution at a final concentration of 25-30 μ g/ml was added and the mixture incubated at 37°C and then read at 15 min, 30 min, and 60 min in a Fluoroscan instrument. The percentage diminution in fluorescence in the presence as compared to the absence of inhibitor is then calculated.